PORT WINE STAIN LASER TREATMENT BUSINESS PLAN

I. Executive Summary

Company Description

Premier Vascular Dermatology Clinic takes its name from a focus on specialized vascular dermatology and clinical excellence. Launching in the United States in 2026, the clinic operates in the medical dermatology sector and provides focused removal and long-term management of vascular birthmarks and port wine stains using state-of-the-art Pulsed Dye Laser and Nd:YAG technologies funded by a $735,000 capital investment. The practice is led by board-certified dermatologists and staffed with highly skilled technicians in a clinically-certified facility to deliver safe, evidence-based care. One clear aim: deliver specialist outcomes general dermatology practices do not offer.

The clinic’s core activities include consultation, staged laser treatment protocols, peri-procedural medical management, and long-term follow-up to maximize clearance and minimize complications. What sets the clinic apart is concentrated clinical expertise, dedicated vascular laser equipment, and a certified clinical environment tailored to high-volume, high-quality vascular care. The target market is pediatric and adult patients with vascular birthmarks and port wine stains seeking specialist treatment. Short-term goals are to establish clinical protocols and patient flow at opening in 2026; the long-term goal is to achieve $8.598 million in annual revenue through clinical excellence and specialized care. One clear metric: reach the stated revenue target through focused specialty services.

Problem

Visible vascular birthmarks and port wine stains cause measurable psychosocial harm—social stigma, reduced self-esteem, and increased healthcare use—which general dermatology practices often fail to address because they lack specialized protocols and technology. One-liner: patients leave standard clinics without satisfactory results.

Access to calibrated pulsed dye laser and Nd:YAG treatment is limited, creating fragmented care and repeated unsuccessful interventions. The market needs a dedicated solution: a 2026 launch that serves a documented first-year demand of $1.65 million in specialized services, supported by a planned $735,000 investment in equipment and a target of $8.598 million annual revenue through focused clinical excellence.

Solution

One-liner: A Houston clinic delivering specialized, non‑invasive vascular treatments with Pulsed Dye Laser and Nd:YAG plus advanced imaging, serving infant referrals through adult revisions and targeting Year 5 revenue of $8.598M.

We close a local care gap by offering focused, high‑expertise treatment for vascular birthmarks where general dermatology and crowded academic centers fall short. Board‑certified dermatologists provide personalized plans, dual‑laser capability treats all skin tones and ages, and serial imaging drives measurable outcomes, shorter waits, and boutique patient experience.

Mission Statement

We empower patients by providing expert, specialized laser care and advanced technology to safely and effectively improve skin appearance and restore confidence. We commit to superior clinical results and compassionate, evidence-based care for people with vascular birthmarks. Our goal is to become the national leader in vascular birthmark treatment through continuous innovation and measurable patient outcomes.

Key Success Factors

Critical operational and financial levers that must be achieved to meet target returns and scale.

• 13‑month payback on $735,000 via sustained high practitioner utilization.
• 12.53% IRR and 17.37% ROE maintained through disciplined pricing and margin control.
• $62,000 annual professional relations budget and a dedicated Liaison Specialist to secure referrals.
• Consistent, high‑quality cosmetic outcomes that drive patient testimonials and digital growth.
• Scalable cost structure targeting $6.58M EBITDA by Year 5.

Financial Summary

Summary of projected financial performance and capital needs for the Executive Summary.

Financial requirements: total initial capex $735,000; maintain minimum cash balance $478,000 (required Apr-26); breakeven achieved Jan-26 (month 1); full payback on initial capital in 13 months. Pricing starts at $850 for lead dermatological services. Anticipated IRR 12.53% with ROE 17.37%.

Financial outlook: strong revenue and EBITDA growth, rapid payback, and a maintained cash cushion for operational stability.

Funding Requirements

We require $1,213,000 to start the clinic—including a $735,000 CapEx package (Vbeam and NdYAG systems), and a maintained minimum cash balance of $478,000; the plan targets $1.65M revenue in 2026 scaling to $8,598,000 in 2030, EBITDA growing from $964,000 to $6,580,000, breakeven in month 1, and a 13-month payback on initial capital.